iosBio receives UK grant to develop oral vaccine against Nipah virus PRESS RELEASE iosBio receives UK grant to develop oral vaccine against Nipah virus Zoonotic virus often cited as future pandemic threat and requiring urgent R&D actioniosBio’s oral vaccine...

iosBio appoints Patricia Londono-Hayes as Chief Development Officer PRESS RELEASE iosBio appoints Patricia Londono-Hayes as Chief Development Officer Oral vaccines and biotherapeutics company strengthens senior leadership team with new role to drive priority...

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19   PRESS RELEASE iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19             iosBio licenses its OraProTM...

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19   PRESS RELEASE iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19             iosBio licenses its OraProTM...

Stabilitech Biopharma announces name change to iosBio PRESS RELEASE Stabilitech Biopharma announces name change to iosBio Burgess Hill, UK, 30 September 2020, STABILITECH BIOPHARMA (the “Company”), a UK-based biotechnology company developing next...